Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Conditions
Keywords
Cutaneous T-cell Lymphoma
Brief summary
The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over low-dose TSEBT alone in participants with mycosis fungoides (MF) Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.
Detailed description
Vorinostat is a histone deacetylase inhibitor (HDAC) that is FDA-approved for treatment of mycosis fungoides (MF), and has shown activity as a radiation-sensitizer in preclinical studies. Treatment of various cell lines \[glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), melanoma\] has shown that pretreatment with vorinostat had a significant effect on radiation kill. This effect is believed to be secondary to multiple mechanisms that may involve antiproliferative growth inhibition and effects on DNA repair after exposure to radiation. A histone deacetylase inhibitor such as vorinostat may act as a radiosensitizer by modulating the expression of single- and double-strand DNA repair proteins such as KU67, KU86, H2AX, and Rad50. These DNA repair proteins are enzymes of that repair radiation-induced damage. The decrease in these DNA repair enzymes is thought to be the key mechanism of sensitization. Down-regulation of several key proteins involved in the nonhomologous end joining pathway is thought to generate a G2/M checkpoint blockade. Vorinostat may also cause an open chromatin structure increasing the effect of radiation damage to DNA. This is exemplified by the finding that there is a prolonged H2AX phosphorylation and H2AX foci formation. The mechanism producing this prolongation of H2AX foci is thought to contribute to the damage, and thus killing effect of the radiation. In the pivotal phase 2 trial of vorinostat, an overall response rate of nearly 30% was reported. The median time to progression was 4.9 months overall, and 9.8 months for MF stage IIB or higher responders. Through hyperacetylation of both histone and non-histone proteins, vorinostat is felt to exert its anti-tumor activity via several mechanisms, including cell cycle arrest, induction of apoptosis, reactive oxygen species generation, cell differentiation, and angiogenesis inhibition. Importantly, a number of pre-clinical studies have reported on the potential of vorinostat to enhance radiosensitivity of several different human tumor cell lines. The rational for clinical trial investigating combination of vorinostat and TSEBT not only comes from their underlying mechanism for potential synergy as suggested by prior in-vitro studies but also due to general therapeutic advantage derived from their non-overlapping toxicities. Recent results from a phase 1 dose-escalation trial combining palliative pelvic radiation (30 Gy in 3 Gy fractions over 2 weeks) and vorinostat in study participants with histologically-confirmed intrapelvic gastrointestinal carcinoma. Sixteen participants were enrolled into cohorts of escalating vorinostat dose (100 mg, 200 mg, 300 mg, and 400 mg daily). The most common adverse events were grade 1 and 2, among which fatigue and gastrointestinal events were most common. Grade 3 adverse events included fatigue (n = 5), hyponatremia (n = 1), hypokalemia (n = 1), and acneiform rash (n = 1). Of these, treatment related grade 3 events \[ie, dose limiting toxicities (DLT)\] were observed in 1 of 6 participants at vorinostat 300 mg daily (fatigue and anorexia), and in 2 of 6 participants at the 400 mg daily dose. As a result, the maximum tolerated dose of vorinostat in combination with palliative radiotherapy was determined to be 300mg daily. The study concluded that vorinostat can be safely combined with short term palliative radiotherapy. It should be noted that the adverse events observed in the combination trial overlap with the toxicity profile of vorinostat listed in the package insert. Anecdotal experience in a patient who was failing standard course of TSEBT is relevant and is described here. This patient's skin lesions were progressing towards the latter half of his TSEBT course, thus, vorinostat was initiated and overlapped with TSEBT in the last 2 weeks. The patient tolerated the combination well without any worsening skin reactions and his skin lesions cleared completely. At one year follow-up, his skin is still in complete remission. Another patient received a combination of romidepsin, another (HDAC) inhibitor, and low-dose (12 Gy) TSEBT. He had CR after the addition of TSEBT, while his skin lesions were stable on romidepsin alone. Based on preclinical, early clinical data and anecdotal experience, it is anticipated that vorinostat in combination with TSEBT can be administered safely and will be tolerated in participants with MF. In addition, within the recognized limits of a phase 1-2 clinical trial, this study may provide an assessment of the anti-tumor activity of vorinostat in combination with TSEBT in participants with MF and thus allow us to evaluate the radiation-enhancing potential of vorinostat. This study is a multicenter phase 1-2, randomized, 2-arm trail exploring the efficacy of TSEBT 12 Gy alone vs TSEBT 12 Gy + vorinostat. 12 Gy was selected for this study because it is effective as a rapid debulking agent (with overall response rates of near 100% in the retrospective study and ongoing clinical trial) and can be administered conveniently over 3 weeks. Because of the diminished clinical CR rates associated with TSEBT doses \< 30 Gy, it is proposed that combining TSEBT 12 Gy with vorinostat will lead to significantly higher complete response (CR) rates, longer time-to-progression (TTP), and improved quality of life as compared to TSEBT 12 Gy alone. Based on the retrospective study and preliminary experience in the ongoing 12 Gy TSEBT trial, it is hypothesized that 12 Gy is an adequate dose to achieve clinically meaningful outcomes and that the vorinostat may enhance its clinical efficacy while minimizing radiation-associated toxicities due to the shortened treatment duration. Participants are stratified by MF stage as follows. * Stage IB: \ 10 % skin involvement, with up to 1000/mm3 clone+ Sezary cells in blood. * Stage IIA: Up to 10 % skin involvement, with up to 1000/mm3 clone+ Sezary cells in blood and clinically abnormal peripheral lymph nodes. * Stage IIB: One or more tumors 1 cm in diameter, with up to 1000/mm3 clone+ Sezary cells in blood and clinically abnormal peripheral lymph nodes. * Stage IIIB: Skin erythema \>80 % body surface area, with up to 1000/mm3 clone+ Sezary cells in blood and clinically abnormal peripheral lymph nodes. For detailed staging information, see References: Olsen E, et al. Blood. 2007;110:1713-1722. PMID: 17540844
Interventions
TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
DRUGVorinostat
Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy-confirmed mycosis fungoides (MF); clinical stage IB; IIA; IIB; or IIIB. * Patients must have failed or have been intolerant to at least one prior systemic or skin-directed therapy. This may include topical steroids if used as primary therapy for MF. * 18 years of age or older. * Eastern Cooperative Oncology Group (ECOG) of ≤ 2. * White blood cell (WBC) \> 2000/uL * Platelet count \> 75,000/mm3 * Absolute neutrophil count (ANC) \> 1000. * Bilirubin ≤ 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤ 2.5 x UNL * Alanine aminotransferase (ALT) ≤ 2.5 x UNL * Alkaline phosphatase (liver fraction) ≤ 2.5 x ULN * Creatinine ≤ 1.5 x UNL OR creatinine clearance ≤ 60 mL/min for patients with creatinine levels \> 1.5 x institutional ULN * Potassium level between 3.5 and 4.5 * Magnesium level between 1.5 and 2.5 * Required washout period for prior therapies * Topical therapy: 2 weeks * Systemic biologic, monoclonal antibody, or chemotherapy: 4 weeks * Phototherapy or radiotherapy (excluding TSEBT): 4 weeks * Other investigational therapy: 4 weeks * Note: patients with rapidly progressive disease may be treated earlier than required washout period; however, such circumstance must be discussed and approved by the protocol director at the primary site (Stanford). * Women of child-bearing potential (WOCBP) must have negative serum pregnancy test. * WOCBP must agree to use effective contraception, defined as oral contraceptives, intrauterine devices, double barrier method (condom plus spermicide or diaphragm) or abstain from sexual intercourse. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for 12 consecutive months). * Male subjects must be willing to use an appropriate method of contraception (eg, condoms) or abstain from sexual intercourse and inform any sexual partners that they must also use a reliable method of contraception (eg, birth control pills) during the study. * Ability to understand and sign a written informed consent document. * Ability to comply with the treatment schedule
Exclusion criteria
* Prior courses of TSEBT (Note : localized skin-directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study). * Concomitant use of any anti-cancer therapy or immune modifier. * Receiving colony stimulating factors. * Prior allogeneic or autologous transplant. * Active infection or have received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug. * Known history of human immunodeficiency virus (HIV), hepatitis B or C. * History of prior malignancy with the exception of cervical intraepithelial neoplasia, non-melanoma skin cancer, and adequately treated localized prostate carcinoma (PSA \< 1.0). Patients with a history of other malignancies must have undergone potentially curative therapy and have no evidence of that disease for 5 years. * Uncontrolled intercurrent illness, condition, or circumstances that could limit compliance with the study, including, but not limited to the following: active infection, acute or chronic graft versus host disease, symptomatic congestive heart failure, unstable angina pectoris, medically significant cardiac arrhythmia, uncontrolled diabetes mellitus or hypertension, or psychiatric conditions. * Medically significant cardiac event in prior 6 months (ie, myocardial infarction, cardiac surgery. * Congenital long QT syndrome. * QTc interval \> 480 msec on screening ECG. * Proven or suspected stage IV disease including patients with B2 (Sezary syndrome); N3 (frank LN disease); or M1 (visceral disease) categories; presence of reactive or dermatopathic lymphadenopathy (N1-2) or limited blood involvement (B1) is permitted. * Pregnant or lactating. * Unwilling to use reliable birth control methods. * Any other medical issue, including laboratory abnormalities, deemed by the Investigator to be likely to interfere with patient participation. * Unwilling or unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Clinical Response (CCR) | Week 8 | Complete Clinical Response (CCR) at week 8 as determined by an Modified Severity-Weighted Assessment Tool (mSWAT) score of 0. mSWAT is an objective, quantitative, severity-weighted method to assess the extent of mycosis fungoides (MF) lesions, and is determined by total body surface area (%TBSA) of the lesion by a severity-weighting factor (1 = patch; 2 = plaque; 4 = tumor). O% TBSA produces a product of 0, indicating complete response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Adverse events were collected through 30 days after the last day of study therapy, or until the patient received an non-study treatment for lymphoma, whichever occurred first. | Adverse events occurring at least 10% out of evaluable participants, and it's corresponding rate in the opposing arm. |
| Clinical Response Rate (CRR) | Week 8 | Clinical Response Rate (CRR) at week 8 as determined by an Modified Severity-Weighted Assessment Tool (mSWAT) score of 0, consisting of complete response (CR) rate; partial response (PR) rate; stable disease (SD) rate; or progressive disease (PD) rate. CR = 100% clearance of skin disease (mSWAT score = 0) PR = 50%to \<100% clearance of skin disease as measured by \> 50% decrease of mSWAT score compared with baseline SD = Not CR, PR, or PD PD = Whichever is met first of: 1. \> 25% increase in skin disease from baseline as measured by \> 25% increase of mSWAT score compared with baseline 2. New tumor (T3) lesions in patients without prior T3 lesions (T1, T2, T4) or 3. In responders (confirmed), increase in skin disease over nadir by 50% of baseline as measured by mSWAT score of \> \[nadir + \> 50% of baseline\] 4. Relapse applies to any new disease after confirmed CR |
| Duration of Clinical Benefit (Per Protocol Follow-up) | 48 weeks after completion of treatment | Duration of clinical benefit represents the period of time that clinical response was maintained. Duration of clinical benefit is reported as the median period of time from the initiation of treatment until progressive disease, as measured by the mSWAT skin assessment, and censored at the final per-protocol assessment (48 weeks) |
| Duration of Clinical Benefit (Supplemental Follow-up) | 140 weeks | Duration of clinical benefit represents the period of time that clinical response was maintained. Duration of clinical benefit is reported as the median period of time from the initiation of treatment or until progressive disease, as measured by the mSWAT skin assessment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TSEBT Only • TSEBT as 12 grey (Gy), fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. | 14 |
| TSEBT Plus Vorinostat * TSEBT as 12 grey (Gy), fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks.
* Vorinostat 400 mg/day concurrent and continuing for 8 weeks total. | 14 |
| Total | 28 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Patient started non-protocol therapy | 0 | 1 |
Baseline characteristics
| Characteristic | TSEBT Only | TSEBT Plus Vorinostat | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 5 Participants | 2 Participants | 7 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants | 12 Participants | 21 Participants |
| Clinical Stage Mycosis fungoides, Stage IB | 9 Participants | 8 Participants | 17 Participants |
| Clinical Stage Mycosis fungoides, Stage IIA | 2 Participants | 2 Participants | 4 Participants |
| Clinical Stage Mycosis fungoides, Stage IIB | 2 Participants | 3 Participants | 5 Participants |
| Clinical Stage Mycosis fungoides, Stage IIIB | 1 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants | 11 Participants | 21 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 10 Participants | 10 Participants | 20 Participants |
| Sex: Female, Male Female | 7 Participants | 6 Participants | 13 Participants |
| Sex: Female, Male Male | 7 Participants | 8 Participants | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 14 / 14 | 14 / 14 |
| serious Total, serious adverse events | 1 / 14 | 0 / 14 |
Outcome results
Primary
Complete Clinical Response (CCR)
Complete Clinical Response (CCR) at week 8 as determined by an Modified Severity-Weighted Assessment Tool (mSWAT) score of 0. mSWAT is an objective, quantitative, severity-weighted method to assess the extent of mycosis fungoides (MF) lesions, and is determined by total body surface area (%TBSA) of the lesion by a severity-weighting factor (1 = patch; 2 = plaque; 4 = tumor). O% TBSA produces a product of 0, indicating complete response.
Time frame: Week 8
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TSEBT Only | Complete Clinical Response (CCR) | 3 Participants |
| TSEBT Plus Vorinostat | Complete Clinical Response (CCR) | 3 Participants |
Secondary
Clinical Response Rate (CRR)
Clinical Response Rate (CRR) at week 8 as determined by an Modified Severity-Weighted Assessment Tool (mSWAT) score of 0, consisting of complete response (CR) rate; partial response (PR) rate; stable disease (SD) rate; or progressive disease (PD) rate. CR = 100% clearance of skin disease (mSWAT score = 0) PR = 50%to \<100% clearance of skin disease as measured by \> 50% decrease of mSWAT score compared with baseline SD = Not CR, PR, or PD PD = Whichever is met first of: 1. \> 25% increase in skin disease from baseline as measured by \> 25% increase of mSWAT score compared with baseline 2. New tumor (T3) lesions in patients without prior T3 lesions (T1, T2, T4) or 3. In responders (confirmed), increase in skin disease over nadir by 50% of baseline as measured by mSWAT score of \> \[nadir + \> 50% of baseline\] 4. Relapse applies to any new disease after confirmed CR
Time frame: Week 8
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TSEBT Only | Clinical Response Rate (CRR) | Stable Disease | 3 Participants |
| TSEBT Only | Clinical Response Rate (CRR) | Complete Response (CR) | 3 Participants |
| TSEBT Only | Clinical Response Rate (CRR) | Progressive Disease | 0 Participants |
| TSEBT Only | Clinical Response Rate (CRR) | Partial Response | 8 Participants |
| TSEBT Plus Vorinostat | Clinical Response Rate (CRR) | Progressive Disease | 0 Participants |
| TSEBT Plus Vorinostat | Clinical Response Rate (CRR) | Stable Disease | 0 Participants |
| TSEBT Plus Vorinostat | Clinical Response Rate (CRR) | Complete Response (CR) | 3 Participants |
| TSEBT Plus Vorinostat | Clinical Response Rate (CRR) | Partial Response | 10 Participants |
Secondary
Duration of Clinical Benefit (Per Protocol Follow-up)
Duration of clinical benefit represents the period of time that clinical response was maintained. Duration of clinical benefit is reported as the median period of time from the initiation of treatment until progressive disease, as measured by the mSWAT skin assessment, and censored at the final per-protocol assessment (48 weeks)
Time frame: 48 weeks after completion of treatment
Population: The data are reported for the per-protocol period of follow-up (48 weeks).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TSEBT Only | Duration of Clinical Benefit (Per Protocol Follow-up) | 48 Weeks |
| TSEBT Plus Vorinostat | Duration of Clinical Benefit (Per Protocol Follow-up) | 28 Weeks |
Secondary
Duration of Clinical Benefit (Supplemental Follow-up)
Duration of clinical benefit represents the period of time that clinical response was maintained. Duration of clinical benefit is reported as the median period of time from the initiation of treatment or until progressive disease, as measured by the mSWAT skin assessment.
Time frame: 140 weeks
Population: The data are reported for the full period for which participant data are available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TSEBT Only | Duration of Clinical Benefit (Supplemental Follow-up) | 125 weeks |
| TSEBT Plus Vorinostat | Duration of Clinical Benefit (Supplemental Follow-up) | 28 weeks |
Secondary
Safety and Tolerability as Measured by Severity and Frequency of Adverse Events
Adverse events occurring at least 10% out of evaluable participants, and it's corresponding rate in the opposing arm.
Time frame: Adverse events were collected through 30 days after the last day of study therapy, or until the patient received an non-study treatment for lymphoma, whichever occurred first.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Vomiting | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Diarrhea | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Extremity Pain | 9 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Ocular Irritation | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Alopecia | 7 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Radiation Dermatitis | 1 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Nausea | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Thrombocytopenia | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Xerosis/Dry Skin | 1 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Anorexia | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Dysgeusia | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Dizziness | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Fatigue | 4 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Lymphopenia | 0 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Nail Changes | 4 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Pedal Edema | 2 Number of patients |
| TSEBT Only | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Skin Pain | 1 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Pedal Edema | 1 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Skin Pain | 2 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Vomiting | 2 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Xerosis/Dry Skin | 2 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Alopecia | 10 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Fatigue | 10 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Extremity Pain | 6 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Nausea | 8 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Dysgeusia | 4 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Nail Changes | 1 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Diarrhea | 3 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Ocular Irritation | 3 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Radiation Dermatitis | 3 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Thrombocytopenia | 3 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Anorexia | 2 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Dizziness | 2 Number of patients |
| TSEBT Plus Vorinostat | Safety and Tolerability as Measured by Severity and Frequency of Adverse Events | Lymphopenia | 2 Number of patients |